期刊
NATURE MEDICINE
卷 20, 期 7, 页码 741-747出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3552
关键词
-
资金
- University of Liege
- Fonds pour la Recherche Industrielle et Agricole (FRIA), Belgium
- Fonds National de la Recherche Scientifique (FNRS), Belgium
- Belgian Federal Science Policy Office [IUAP06/30]
- Neoangio program from the 'Service Public de Wallonie' [616476]
- Belgian Foundation against Cancer, Televie
- Leon Fredericq Fund
- Centre Anticancereux (Liege, Belgium)
- Dutch Cancer Society [UM2008-4101, VU2009-4358]
- Belgian Science Policy (IAP) [P7/03]
- Leducq Network of Excellence
- Flanders Research Foundation (FWO)
- Foundation against Cancer, European Research Council Advanced Research [EU-ERC269073]
- long-term structural Methusalem - Flemish Government
The N-terminal fragment of prolactin (16K PRL) inhibits tumor growth by impairing angiogenesis, but the underlying mechanisms are unknown. Here, we found that 16K PRL binds the fibrinolytic inhibitor plasminogen activator inhibitor-1 (PAI-1), which is known to contextually promote tumor angiogenesis and growth. Loss of PAI-1 abrogated the antitumoral and antiangiogenic effects of 16K PRL. PAI-1 bound the ternary complex PAI-1-urokinase-type plasminogen activator (uPA)-uPA receptor (uPAR), thereby exerting antiangiogenic effects. By inhibiting the antifibrinolytic activity of PAI-1, 16K PRL also protected mice against thromboembolism and promoted arterial clot lysis. Thus, by signaling through the PAI-1-uPA-uPAR complex, 16K PRL impairs tumor vascularization and growth and, by inhibiting the antifibrinolytic activity of PAI-1, promotes thrombolysis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据